Pharmacy World and Science

, Volume 19, Issue 4, pp 197–201 | Cite as

Stability of nystatin in mouthrinses; effect of pH, temperature, concentration and colloidal silver addition, studied using an in vitro antifungal activity.

  • N. Vermerie
  • C. Malbrunot
  • M. Azar
  • P. Arnaud


Alkaline low concentration nystatin mouthrinses extemporanely prepared can be used to treat oropharyngeal candidiasis in immunodeficient patients. However, their expiration dates are not distinctly determined.

The stability of nystatin, added (as Mycostatine™) at a concentration of 14 400 U/ml in 10−4 N hydrochloric acid, purified water and 1.4% injectable sodium hydrogen carbonate with or without 0.002% colloidal silver (an antiseptic agent added because of its known antifungal potency) was studied after storage in tinted glass bottles at 5 °C and 22 °C over 11 days, and compared with reconstituted 100 000 U/ml aqueous Mycostatine™ oral suspension. At 2, 4, 7, 9, and 11 days after preparation. Samples were tested for pH, microbial contamination, and assayed by an in vitro microbiological test.

Neither significant variation of pH nor microbial contamination were in evidence. Nystatin 14 400 U/ml maintained at least 90% of its initial concentration for 4 days in acid at both temperatures, for 7 days (5 °C) and 4 days (22 °C) in aqueous and alkaline environments, for 9 days (5 °C) and 7 days (22 °C) in 1.4% injectable sodium hydrogen carbonate containing colloidal silver which showed an antifungal potency. The 100 000 U/ml aqueous Mycostatine™ oral suspension was stable for 9 days and 4 days at 5 °C and 22 °C respectively.

An ambulant patient can keep a low concentration alkaline antifungal mouthrinse at home for a week at 5 °C.

Antifungal mouthrinse Colloidal silver Drug concentration Drug stability Nystatin Sodium hydrogen carbonate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Meunier-Carpentier F. Chemoprophylaxis of fungal infec-tions. Am J Med 1984;76:652–65.Google Scholar
  2. 2.
    Quintiliani R, Owens NJ, Quercia RA, Klimek JJ, Nightingale CH. Treatment and prevention of oropharyngal candidiasis. Am J Med 1984;77(D4):44–8.Google Scholar
  3. 3.
    Brandell R, Chase SL, Cohn JR. Treatment of oral candidiasis with amphotericin B solution. Clin Pharm 1988;7:70–2.Google Scholar
  4. 4.
    Thompson J, Wingfield HJ, Cosgrove RF, Hugues BO, Turner-Warwick ME. Assessment of oral candidiasis in patients with respiratory disease and efficacy of a new nystatin formula-tion. Br Med J 1986;292:1699–1700.Google Scholar
  5. 5.
    Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexi-dine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1992;73(6):682–9.Google Scholar
  6. 6.
    Vincent I, Schmit B, Houze S, Benhaiem N, Jacques L, Taburet AM. Bains de bouche antifongiques: étude de stabilité. J Pharm Clin 1995;14:106–11.Google Scholar
  7. 7.
    Favet J, Zelger GL. Etude de l'activité antifongique in vitrod'une suspension à base de nystatine destinée aux soins de bouche de patients cancéreux. J Pharm Clin 1994;13:20–6.Google Scholar
  8. 8.
    The Merck Index. 11th rev ed. Rahway, NJ: Merck and Co Inc., S. Budavari, 1989:1067.Google Scholar
  9. 9.
    Martindale The Extra Pharmacopoeia. 30th rev ed. London: The Pharmaceutical Press, JEF. Reynolds, 1993:330 and 1411.Google Scholar
  10. 10.
    American Hospital Formulary Service 95 Drug Information. 37th rev ed. Bethesda: American Society of Health-System Pharmacists Inc, GK. Mc Evoy, 1995:97–8.Google Scholar
  11. 11.
    Physicians' Desk Reference. 45th rev ed. Montvale: Medical Economics Data Production Company, ER Barhnart, 1991:2151.Google Scholar
  12. 12.
    Physicians' Desk Reference. 49th rev ed. Montvale: Medical Economics Data Production Company, 1995:1812.Google Scholar
  13. 13.
    Fleurette J, Freney J, Reverdy ME. Antisepsie et désinfection. Paris: ESKA, 1995:275–8.Google Scholar
  14. 14.
    Crémieux A, Fleurette J, Fourtillan JB, Joly B, Soussy CJ. Les antiseptiques. Bases microbiologiques de leur utilisation. Mérignac: Laboratoire Sarget, 1982:130.Google Scholar
  15. 15.
    Titrage microbiologique des antibiotiques. Pharmacopée Européenne. 2ème ed. Sainte-Ruffine: Maisonneuve SA, 1993.Google Scholar
  16. 16.
    Manual of Clinical Microbiology. 4th rev ed. Washington, DC: American Society for Microbiology, 1985:88.Google Scholar
  17. 17.
    Trissel LA. Handbook on Injectable Drugs. 6th rev ed. Bethesda, MD: American Society of Hospital Pharmacists, Inc, 1990.Google Scholar
  18. 18.
    Hamilton-Miller JMT. The effect of pH and temperature on the stability and bioactivity of nystatin and amphotericin B. J Pharm Pharmac 1973;25:401–7.Google Scholar
  19. 19.
    Van Doorne H, Bosch EH. Stability and in vitro activity of nys-tatin and its c-cyclodextrin complex against candida albi-cans. Int J Pharm 1991;73:43–9.Google Scholar
  20. 20.
    Dupont B. Candidoses, cryptococcoses, aspergilloses. Paris: Ceprime, 1981:18.Google Scholar
  21. 21.
    Vaillant L, De Closets F, Laglaoui M, Muller C, Goga D, Lorette G. Candidoses buccales des adultes de plus de 65 ans: absence d'efficacité des bains des bouches à l'eau bicarbonatée. Med Chir Dig 1992;21(3):139.Google Scholar
  22. 22.
    Dorvault F. L'Officine. 23ème ed. Paris: Vigot, 1995:461.Google Scholar
  23. 23.
    Simoneti N, Simoneti G, Bougnol F, Scalzo M. Electrochemical Ag+ for preservative use. Appl Environ Microbiol 1992;58:3834–6.Google Scholar
  24. 24.
    Préparations antiseptiques. Pharmacopée Française. Xème ed. Sainte-Ruffine: Maisonneuve SA, 1990.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • N. Vermerie
    • 1
  • C. Malbrunot
    • 2
  • M. Azar
    • 1
  • P. Arnaud
    • 1
  1. 1.Pharmacy ServiceJean Verdier Hospital AP-HPBondyFrance
  2. 2.Microbiology ServiceGilles de Corbeil HospitalCorbeil-EssonnesFrance

Personalised recommendations